探究肺癌临床诊断中肿瘤标志物的应用效果  

Application Effect of Tumor Markers in Clinical Diagnosis of Lung Cancer

作　　者：刘光明[1] 丘仲柳[1] 陈世豪[1] 赖天寿 谭柏松[1] 李健茹[1] LIU Guangming;QIU Zhongliu;CHEN Shihao(Jiangmen Xinhui People＇s Hospital,Jiangmen 529100,China)

机构地区：[1]广东省江门市新会区人民医院,广东江门529100

出　　处：《中国医学创新》2018年第27期54-57,共4页Medical Innovation of China

基　　金：国家卫生计生委医药卫生科技发展研究中心(W2015JG10)

摘　　要：目的:探析肿瘤标志物在肺癌临床诊断中的应用价值。方法:选取2014年8月-2017年8月本院收治的100例肺癌患者为观察1组,以45例肺部良性病变患者为观察2组,以同期到本院接受检查的50名健康人为对照组。三组研究对象均接受癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、胃泌素释放肽前体(Pro-GRP)、促血管生成素-2(Ang-2)肿瘤标志物检查,对三组的检查结果及肿瘤标志物的诊断价值进行对比分析。结果:观察1组CEA、CA125、CYFRA21-1、NSE、Pro-GRP、Ang-2检测水平均明显高于观察2组和对照组(P<0.05)。在肺癌分期的诊断上:肺癌Ⅳ期患者六种肿瘤标志物的检测水平均明显高于肺癌Ⅲ期患者,且肺癌Ⅲ期患者的肿瘤标志物检测值均高于Ⅲ期和Ⅰ期患者(P<0.05)。结论:在肺癌的临床诊断中,肿瘤标志物起到较好的诊断效果,可根据肿瘤标志物的检测结果对病情的发展情况、临床分期、是否发生淋巴结转移和治疗后是否复发进行诊断,可降低临床漏诊、误诊。Objective：To explore the application effect of tumor markers in clinical diagnosis of lung cancer.Method：A total of 100 patients with lung cancer obtained treatment in our hospital form August 2014 to August 2017 were selected as Group 1,45 patients with benign pulmonary disease were selected as Group 2 and 50 healthy people were received health examination in our hospital as control group.CEA,CA125,CYFRA21-1, NSE,Pro-GRP and Ang-2 tumor marker examinations were examined among three groups,the results and joint diagnose value of tumor markers were compared and analyzed.Result：The detection levels of CEA,CA125, CYFRA21-1,NSE,Pro-GRP and Ang-2 of Group 1 were significantly higher than those of Group 2 and control group（P〈0.05）.Regarding the diagnosis of lung cancer staging,the detection levels of six types of tumor markers of patients in Ⅳstaging of lung cancer were significantly higher than those of patients in Ⅲ staging of lung cancer,and tumor markers detection levels of Ⅲ staging were also higher than those of patients in Ⅲ and Ⅰ staging of lung cancer（P〈0.05）.Conclusion：Tumor markers give effective diagnosis basis in clinical diagnosis of lung cancer, according to which disease progression,clinical stages,whether there is lymphatic metastasis and whether lung cancer is recurrent or not after treatment can be judged.Thus,tumor marker is able to reduce clinical misdiagnosis and missed diagnosis.

关 键 词：肿瘤标志物 肺癌 淋巴转移 

分 类 号：R734.2[医药卫生—肿瘤]